Model name | Included proteins | Protein name | Uniprot entry name | Uniprot ID | PDB ID | Species | Ligand(s) | Membrane composition | Replicates | Author | Num. of atoms | Software | Force field | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Open | PL-PRO | NSP3 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6W9C | SARS-CoV-2 | 1 | Exscalate4CoV | 4894 | GROMACS 2020 | AMBER 99 | ||
Open | NSP12-NSP7-NSP8 - SARS-CoV-2 Polymerase |
NSP8, NSP7, NSP12 |
Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6M71 | SARS-CoV-2 | 1 | Exscalate4CoV | 138650 | GROMACS 2020 | AMBER 99 | ||
Open | NSP3 | NSP3 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6W02 | SARS-CoV-2 | 1 | Exscalate4CoV | 2506 | GROMACS 2020 | AMBER 99 | ||
Open | NSP9 | NSP9 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6W4B | SARS-CoV-2 | 1 | Exscalate4CoV | 3477 | GROMACS 2020 | AMBER 99 | ||
Open | NSP3 | NSP3 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6W02 | SARS-CoV-2 | 1 | Exscalate4CoV | 2506 | GROMACS 2020 | AMBER 99 | ||
Open | SARS spike receptor binding domain bound with FERR ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12582 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VW1 | SARS-CoV-2 | 1 | Vito Genna | 3004 | GROMACS 2019.1 | None | ||
Open | Human Angiotensin-converting enzyme 2 (ACE2) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9517 | GROMACS 2019.1 | None | ||
Open | SARS spike receptor binding domain | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VW1 | SARS-CoV-2 | 1 | Vito Genna | 3000 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VW1 | SARS-CoV-2 | 1 | Vito Genna | 2985 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VW1 | SARS-CoV-2 | 1 | Adam Hospital | 3008 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VW1 | SARS-CoV-2 | 1 | Adam Hospital | 2995 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VW1 | SARS-CoV-2 | 1 | Adam Hospital | 3006 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VW1 | SARS-CoV-2 | 1 | Adam Hospital | 3010 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VW1 | SARS-CoV-2 | 1 | Adam Hospital | 2999 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with human ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12510 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with Rhinolophus Affinis ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12584 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with FERR ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12586 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with MACR ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12599 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with Pangolin ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12562 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with PUS ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12589 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with SIN1 ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12607 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with SIN2 ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12600 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with SIN3 ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12601 | GROMACS 2019.1 | None | ||
Open | Bat-SARSr-CoV RATG13 spike receptor binding domain bound with ZIBB ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12529 | GROMACS 2019.1 | None | ||
Open | SARS spike receptor binding domain bound with human ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12517 | GROMACS 2019.1 | None | ||
Open | SARS spike receptor binding domain bound with MACR ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12595 | GROMACS 2019.1 | None | ||
Open | SARS spike receptor binding domain bound with Pangolin ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12558 | GROMACS 2019.1 | None | ||
Open | SARS spike receptor binding domain bound with PUS ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12585 | GROMACS 2019.1 | None | ||
Open | SARS spike receptor binding domain bound with SIN1 ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12603 | GROMACS 2019.1 | None | ||
Open | SARS spike receptor binding domain bound with SIN2 ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12596 | GROMACS 2019.1 | None | ||
Open | SARS spike receptor binding domain bound with SIN3 ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12597 | GROMACS 2019.1 | None | ||
Open | SARS spike receptor binding domain bound with ZIBB ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12525 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with human ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12510 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with FERR ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12575 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with MACR ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12588 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with Pangolin ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12551 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with PUS ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12578 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with SIN1 ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12596 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with SIN2 ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12589 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with SIN3 ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12590 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with ZIBB ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12518 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with AFFINIS ACE2 (REAL) |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12573 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with human ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12502 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with FERR ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12567 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with MACR ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12580 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with Pangolin ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12543 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with PUS ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12570 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with SIN1 ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12588 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with SIN2 ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12581 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with SIN3 ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12582 | GROMACS 2019.1 | None | ||
Open | SARS-CoV-2 spike receptor binding domain bound with ZIBB ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Vito Genna | 12510 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain bound with human ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Adam Hospital | 12525 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain bound with human ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Adam Hospital | 12512 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain bound with human ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Adam Hospital | 12523 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain bound with human ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Adam Hospital | 12527 | GROMACS 2019.1 | None | ||
Open | Mutated system of Bat-SARSr-CoV RATG13 spike receptor binding domain bound with human ACE2 |
ACE2, Spike |
Spike glycoprotein, Angiotensin-converting enzyme 2 |
SPIKE_SARS2, ACE2_HUMAN | P0DTC2 Q9BYF1 | 6VW1 |
Homo sapiens, SARS-CoV-2 |
1 | Adam Hospital | 12516 | GROMACS 2019.1 | None | ||
Open | Human Angiotensin-converting enzyme 2 (ACE2), USA | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9517 | GROMACS 2019.1 | None | ||
Open | FERR Angiotensin-converting enzyme 2 (ACE2) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9582 | GROMACS 2019.1 | None | ||
Open | MACR Angiotensin-converting enzyme 2 (ACE2) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9595 | GROMACS 2019.1 | None | ||
Open | Pangolin Angiotensin-converting enzyme 2 (ACE2) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9558 | GROMACS 2019.1 | None | ||
Open | PUS Angiotensin-converting enzyme 2 (ACE2) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9585 | GROMACS 2019.1 | None | ||
Open | SIN1 Angiotensin-converting enzyme 2 (ACE2) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9603 | GROMACS 2019.1 | None | ||
Open | SIN2 Angiotensin-converting enzyme 2 (ACE2) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9596 | GROMACS 2019.1 | None | ||
Open | SIN3 Angiotensin-converting enzyme 2 (ACE2) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9597 | GROMACS 2019.1 | None | ||
Open | ZIBB Angiotensin-converting enzyme 2 (ACE2) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | 1 | Vito Genna | 9525 | GROMACS 2019.1 | None | ||
Open | DESRES 100 µs MD of 3CLpro, no water or ions (100 µs) | NSP5 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6Y84 | SARS-CoV-2 | 1 | D. E. Shaw Research | 9364 | Anton supercomputer specific tools None | DES-Amber | ||
Open | Gromacs 60 ns MD of SARS-CoV-2 spike trimer, All Atom model (60 ns) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | 1 | Dmitry Morozov | 52329 | GROMACS 2018.8 | charmm27 | ||
Open | DESRES-ANTON-10940402 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (aclidinium) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | aclidinium | 1 | D. E. Shaw Research | 9713 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986449 2 µs simulation 1 of 78 FDA approved or investigational drug molecules binding to the ectodomain of human ACE2, no water or ions (afeletecan) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | afeletecan | 1 | D. E. Shaw Research | 9764 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918588 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (amentoflavone) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | amentoflavone | 1 | D. E. Shaw Research | 9708 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930330 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (azathioprine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | azathioprine | 1 | D. E. Shaw Research | 9676 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986305 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (barusiban) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | barusiban | 1 | D. E. Shaw Research | 9772 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985913 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (bekanamycin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | bekanamycin | 1 | D. E. Shaw Research | 9724 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940311 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (bendamustine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | bendamustine | 1 | D. E. Shaw Research | 9694 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986801 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (berzosertib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | berzosertib | 1 | D. E. Shaw Research | 9709 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918574 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (birinapant) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | birinapant | 1 | D. E. Shaw Research | 9764 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10921548 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (brequinar) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | brequinar | 1 | D. E. Shaw Research | 9693 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986755 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (brigatinib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | brigatinib | 1 | D. E. Shaw Research | 9730 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930513 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (bromocriptine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | bromocriptine | 1 | D. E. Shaw Research | 9734 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930315 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (brompheniramine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | brompheniramine | 1 | D. E. Shaw Research | 9689 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940945 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (bunazosin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | bunazosin | 1 | D. E. Shaw Research | 9705 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986295 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (capreomycin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | capreomycin | 1 | D. E. Shaw Research | 9744 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986707 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (ceritinib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | ceritinib | 1 | D. E. Shaw Research | 9725 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-11040472 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (chloroquine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | chloroquine | 1 | D. E. Shaw Research | 9700 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941001 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (cimicoxib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | cimicoxib | 1 | D. E. Shaw Research | 9688 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918446 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (conivaptan) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | conivaptan | 1 | D. E. Shaw Research | 9715 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985309 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (copanlisib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | copanlisib | 1 | D. E. Shaw Research | 9713 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985767 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (dabigatran) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | dabigatran | 1 | D. E. Shaw Research | 9710 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985081 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (dacomitinib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | dacomitinib | 1 | D. E. Shaw Research | 9709 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985418 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (dasatinib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | dasatinib | 1 | D. E. Shaw Research | 9710 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940955 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (delavirdine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | delavirdine | 1 | D. E. Shaw Research | 9711 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940322 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (desvenlafaxine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | desvenlafaxine | 1 | D. E. Shaw Research | 9695 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940392 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (deutivacaftor) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | deutivacaftor | 1 | D. E. Shaw Research | 9707 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918477 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (dimenhydrinate) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | dimenhydrinate | 1 | D. E. Shaw Research | 9691 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930274 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (disopyramide) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | disopyramide | 1 | D. E. Shaw Research | 9705 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985120 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (doxazosin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | doxazosin | 1 | D. E. Shaw Research | 9709 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941126 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (doxazosin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | doxazosin | 1 | D. E. Shaw Research | 9709 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986556 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (e7107) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | e7107 | 1 | D. E. Shaw Research | 9768 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986407 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (elamipretide) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | elamipretide | 1 | D. E. Shaw Research | 9748 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986393 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (elbasvir) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | elbasvir | 1 | D. E. Shaw Research | 9770 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918481 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (eletriptan) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | eletriptan | 1 | D. E. Shaw Research | 9704 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940915 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (elvitegravir) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | elvitegravir | 1 | D. E. Shaw Research | 9704 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940388 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (fluoxetine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | fluoxetine | 1 | D. E. Shaw Research | 9691 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930296 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (fluvastatin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | fluvastatin | 1 | D. E. Shaw Research | 9705 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918487 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (gemifloxacin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | gemifloxacin | 1 | D. E. Shaw Research | 9698 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985758 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (gentamicin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | gentamicin | 1 | D. E. Shaw Research | 9731 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985447 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (imatinib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | imatinib | 1 | D. E. Shaw Research | 9719 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986447 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (ipamorelin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | ipamorelin | 1 | D. E. Shaw Research | 9754 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985229 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (kanamycin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | kanamycin | 1 | D. E. Shaw Research | 9722 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985989 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (KPT-9274) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | KPT-9274 | 1 | D. E. Shaw Research | 9725 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940981 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (lixivaptan) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | lixivaptan | 1 | D. E. Shaw Research | 9705 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930235 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (mefloquine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | mefloquine | 1 | D. E. Shaw Research | 9693 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918449 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (methylnaltrexone) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | methylnaltrexone | 1 | D. E. Shaw Research | 9702 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930143 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (methylprednisolone) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | methylprednisolone | 1 | D. E. Shaw Research | 9707 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918451 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (metronidazole) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | metronidazole | 1 | D. E. Shaw Research | 9671 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918469 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (midazolam) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | midazolam | 1 | D. E. Shaw Research | 9687 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986091 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (modithromycin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | modithromycin | 1 | D. E. Shaw Research | 9775 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986538 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (nafithromycin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | nafithromycin | 1 | D. E. Shaw Research | 9773 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985237 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (netilmicin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | netilmicin | 1 | D. E. Shaw Research | 9728 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918458 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (netupitant) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | netupitant | 1 | D. E. Shaw Research | 9724 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930145 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (nevirapine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | nevirapine | 1 | D. E. Shaw Research | 9684 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930511 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (orphenadrine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | orphenadrine | 1 | D. E. Shaw Research | 9694 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918567 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (panobinostat) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | panobinostat | 1 | D. E. Shaw Research | 9699 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10921546 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (pelitinib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | pelitinib | 1 | D. E. Shaw Research | 9706 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918441 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (perphenazine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | perphenazine | 1 | D. E. Shaw Research | 9704 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986035 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (pimecrolimus) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | pimecrolimus | 1 | D. E. Shaw Research | 9774 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930264 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (pimecrolimus) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | pimecrolimus | 1 | D. E. Shaw Research | 9774 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940352 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (pioglitazone) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | pioglitazone | 1 | D. E. Shaw Research | 9695 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930133 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (pramoxine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | pramoxine | 1 | D. E. Shaw Research | 9699 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940855 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (prazosin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | prazosin | 1 | D. E. Shaw Research | 9700 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940404 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (primaquine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | primaquine | 1 | D. E. Shaw Research | 9691 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940411 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (prochlorperazine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | prochlorperazine | 1 | D. E. Shaw Research | 9700 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940316 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (propylhexedrine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | propylhexedrine | 1 | D. E. Shaw Research | 9683 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918467 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (rabeprazole) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | rabeprazole | 1 | D. E. Shaw Research | 9696 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986389 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (ruzasvir) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | ruzasvir | 1 | D. E. Shaw Research | 9774 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940823 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (sivifene) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | sivifene | 1 | D. E. Shaw Research | 9693 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985087 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (sonidegib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | sonidegib | 1 | D. E. Shaw Research | 9712 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940328 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (ticlopidine) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | ticlopidine | 1 | D. E. Shaw Research | 9682 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940935 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (tivozanib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | tivozanib | 1 | D. E. Shaw Research | 9702 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985687 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (tobramycin) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | tobramycin | 1 | D. E. Shaw Research | 9723 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940308 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (topiramate) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | topiramate | 1 | D. E. Shaw Research | 9693 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986138 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (TT-232) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | TT-232 | 1 | D. E. Shaw Research | 9776 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918575 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (vadimezan) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | vadimezan | 1 | D. E. Shaw Research | 9685 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10986018 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (ziritaxestat) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | ziritaxestat | 1 | D. E. Shaw Research | 9727 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10985437 2 µs simulation of an investigational or FDA approved drug molecule binding to the ectodomain of human ACE2, no water or ions (acalabrutinib) | ACE2 | Angiotensin-converting enzyme 2 | ACE2_HUMAN | Q9BYF1 | 6VW1 | Homo sapiens | acalabrutinib | 1 | D. E. Shaw Research | 9708 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930851 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (zileuton) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | zileuton | 1 | D. E. Shaw Research | 14482 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930523 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (alprostadil) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | alprostadil | 1 | D. E. Shaw Research | 14512 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940986 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (amcinonide) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | amcinonide | 1 | D. E. Shaw Research | 14525 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10942625 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (aprepitant) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | aprepitant | 1 | D. E. Shaw Research | 14512 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10921672 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (atazanavir) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | atazanavir | 1 | D. E. Shaw Research | 14557 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930821 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (atorvastatin) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | atorvastatin | 1 | D. E. Shaw Research | 14529 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10942532 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (atropine) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | atropine | 1 | D. E. Shaw Research | 14499 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941382 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (azilsartan) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | azilsartan | 1 | D. E. Shaw Research | 14506 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930748 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (brigatinib) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | brigatinib | 1 | D. E. Shaw Research | 14534 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940762 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (captopril) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | captopril | 1 | D. E. Shaw Research | 14482 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941841 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (calcifediol) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | calcifediol | 1 | D. E. Shaw Research | 14527 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941424 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (cefamandole nafate) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | cefamandole nafate | 1 | D. E. Shaw Research | 14504 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918686 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (cefixime) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | cefixime | 1 | D. E. Shaw Research | 14497 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941112 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (clobazam) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | clobazam | 1 | D. E. Shaw Research | 14488 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941273 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (CP-195543) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | CP-195543 | 1 | D. E. Shaw Research | 14503 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918731 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (darunavir) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | darunavir | 1 | D. E. Shaw Research | 14529 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941722 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (deferasirox) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | deferasirox | 1 | D. E. Shaw Research | 14496 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10942525 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (dihydroergotamine) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | dihydroergotamine | 1 | D. E. Shaw Research | 14535 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10931330 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (divalproex sodium) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | divalproex sodium | 1 | D. E. Shaw Research | 14480 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918694 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (duloxetine) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | duloxetine | 1 | D. E. Shaw Research | 14495 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10931344 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (efavirenz) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | efavirenz | 1 | D. E. Shaw Research | 14484 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930719 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (fluticasone propionate) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | fluticasone propionate | 1 | D. E. Shaw Research | 14519 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10906572 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (iloprost) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | iloprost | 1 | D. E. Shaw Research | 14511 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941783 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (isocarboxazid) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | isocarboxazid | 1 | D. E. Shaw Research | 14484 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941101 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (ketoconazole) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | ketoconazole | 1 | D. E. Shaw Research | 14518 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10942558 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (lapatinib) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | lapatinib | 1 | D. E. Shaw Research | 14520 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941419 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (levomefolate calcium) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | levomefolate calcium | 1 | D. E. Shaw Research | 14510 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941234 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (lometrexol) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | lometrexol | 1 | D. E. Shaw Research | 14508 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10931493 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (lomibuvir) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | lomibuvir | 1 | D. E. Shaw Research | 14520 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10932268 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (megestrol acetate) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | megestrol acetate | 1 | D. E. Shaw Research | 14514 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10906575 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (methsuximide) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | methsuximide | 1 | D. E. Shaw Research | 14482 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918707 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (nebivolol) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | nebivolol | 1 | D. E. Shaw Research | 14509 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10906602 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (naloxone) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | naloxone | 1 | D. E. Shaw Research | 14500 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10942574 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (nilutamide) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | nilutamide | 1 | D. E. Shaw Research | 14486 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930676 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (nitazoxanide) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | nitazoxanide | 1 | D. E. Shaw Research | 14484 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941210 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (pelitrexol) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | pelitrexol | 1 | D. E. Shaw Research | 14508 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941177 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (raltitrexed) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | raltitrexed | 1 | D. E. Shaw Research | 14506 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941364 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (rebamipide) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | rebamipide | 1 | D. E. Shaw Research | 14494 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941282 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (recoflavone) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | recoflavone | 1 | D. E. Shaw Research | 14499 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10921687 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (ritonavir) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | ritonavir | 1 | D. E. Shaw Research | 14552 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10940767 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (rivaroxaban) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | rivaroxaban | 1 | D. E. Shaw Research | 14501 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10942509 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (tadalafil) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | tadalafil | 1 | D. E. Shaw Research | 14502 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10931335 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (telaprevir) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | telaprevir | 1 | D. E. Shaw Research | 14556 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10931329 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (tenofovir) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | tenofovir | 1 | D. E. Shaw Research | 14487 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10918688 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (terazosin) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | terazosin | 1 | D. E. Shaw Research | 14508 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10906555 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (treprostinil) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | treprostinil | 1 | D. E. Shaw Research | 14515 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941754 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (triazolam) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | triazolam | 1 | D. E. Shaw Research | 14489 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10930743 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (vorapaxar) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | vorapaxar | 1 | D. E. Shaw Research | 14523 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941318 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (AZD-8330) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | AZD-8330 | 1 | D. E. Shaw Research | 14495 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | DESRES-ANTON-10941772 2 µs simulation of an investigational or FDA approved drug molecule binding to a construct of the SARS-CoV-2 trimeric spike protein, no water or ions (cobimetinib) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | cobimetinib | 1 | D. E. Shaw Research | 14506 | Anton supercomputer specific tools None | Amber ff99SB-ILDN | |
Open | Spike protein in the Open state (N165A / N234A mutations) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | 1 | Amaro Lab | 71294 | NAMD 2.14 | CHARMM36 N/D | ||
Open | Spike protein in the Open state | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | 1 | Amaro Lab | 72759 | NAMD 2.14 | CHARMM36 N/D | ||
Open | Spike protein in the Closed state | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | 1 | Amaro Lab | 72759 | NAMD 2.14 | CHARMM36 N/D | ||
Open | Spike protein bound to the human ACE2 receptor |
ACE2, Spike |
Angiotensin-converting enzyme 2, Spike glycoprotein |
ACE2_HUMAN, SPIKE_SARS2 | Q9BYF1 P0DTC2 | 6M0J |
Homo sapiens, SARS-CoV-2 |
1 | California State University, Los Angeles and Virginia Tech | 117028 | Amber18 Pmem Cuda N/D | Amber ff14SB N/D | ||
Open | Fully-glycosylated full-length S protein model (model 6VSB_1_1_1) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | Cholesterol, DPP, POP | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 332712 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VSB_1_1_2) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 338232 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VSB_1_2_1) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 332712 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VSB_1_2_2) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 338232 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VSB_2_1_1) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 332712 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VSB_2_1_2) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 338232 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VSB_2_2_1) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 332712 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VSB_2_2_2) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VSB | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 338232 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VXX_1_1_1) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 332712 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VXX_1_1_2) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 338232 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VXX_1_2_1) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 332712 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VXX_1_2_2) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 338232 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VXX_2_1_1) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 332712 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VXX_2_1_2) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 338232 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VXX_2_2_1) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 332712 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Fully-glycosylated full-length S protein model (model 6VXX_2_2_2) | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6VXX | SARS-CoV-2 | Cholesterol, DPP, POP, PSM | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 338232 | GROMACS 2019.2 | CHARMM36m N/D | |
Open | Apo SARS-CoV-2 PLPro (from PDB 6WRH C-chain) | NSP3 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6WRH | SARS-CoV-2 | 1 | Chang group, University of California, Riverside | 4897 | Amber18 2.14 | Amber ff14SB N/D | ||
Open | Apo SARS-CoV-2 PLPro (from PDB 6W9C C-chain) | NSP3 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6W9C | SARS-CoV-2 | 1 | Chang group, University of California, Riverside | 4897 | Amber18 N/D | Amber ff14SB N/D | ||
Open | 3k bound SARS-CoV-2 PLPro | NSP3 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6W9C | SARS-CoV-2 | S88 | 1 | Chang group, University of California, Riverside | 4954 | Amber18 N/D | Amber ff14SB-GAFF2 N/D | |
Open | NS8 in aqueous solution | ORF8 | ORF8 protein | NS8_SARS2 | P0DTC8 | 7JTL | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 67873 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | Envelope small membrane protein in aqueous solution | E | Envelope small membrane protein | VEMP_SARS2 | P0DTC4 | 7K3G | SARS-CoV-2 | POPC | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 62013 | AceMD 3.2.3 | CHARMM36 2019 | |
Open | NSP1 in aqueous solution | NSP1 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 7k3n | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 21343 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | NSP10 in aqueous solution | NSP10 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6ZCT | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 23133 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | Nucleocapsid dimerization domain P21 form in aqueous solution | N | Nucleoprotein | NCAP_SARS2 | P0DTC9 | 6WZQ | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 44268 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | ORF7a in aqueous solution | ORF7a | ORF7a protein | NS7A_SARS2 | P0DTC7 | 6W37 | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 21397 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | Helicase NSP13 in aqueous solution | NSP13 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6ZSL | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 170510 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | NendoU NSP15 in aqueous solution | NSP15 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6VWW | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 88694 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | NSP16 in aqueous solution | NSP16 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6W4H | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 108754 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | ORF3A in aqueous solution | ORF3a | ORF3a protein | AP3A_SARS2 | P0DTC3 | 6XDC | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 105393 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | ORF9B in aqueous solution (missing loops modelled) | ORF9b | ORF9b protein | ORF9B_SARS2 | P0DTD2 | 6Z4U | SARS-CoV-2 | 1 | Institut Hospital del Mar d'Investigacions Mèdiques | 70521 | AceMD 3.2.3 | CHARMM36 2019 | ||
Open | Main Protease (Mpro) in Complex with ML188 (no mutation) | NSP5 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 7L0D | SARS-CoV-2 | ML188 | 3 | Institut Hospital del Mar d'Investigacions Mèdiques | 83351 | AceMD 3.2.3 | CHARMM36 2019 | |
Open | Main Protease (Mpro) in Complex with ML188 (A191V mutation) | NSP5 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 7L0D | SARS-CoV-2 | ML188 | 3 | Institut Hospital del Mar d'Investigacions Mèdiques | 83402 | AceMD 3.2.3 | CHARMM36 2019 | |
Open | Main Protease (Mpro) in Complex with ML188 (T24A mutation) | NSP5 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 7L0D | SARS-CoV-2 | ML188 | 3 | Institut Hospital del Mar d'Investigacions Mèdiques | 83338 | AceMD 3.2.3 | CHARMM36 2019 | |
Open | Macrodomain (NSP3) in complex with ADP-ribose | NSP3 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6WOJ | SARS-CoV-2 | ADP-ribose | 3 | Institut Hospital del Mar d'Investigacions Mèdiques | 33414 | AceMD 3.2.3 | CHARMM36 2019 | |
Open | Macrodomain (NSP3) in complex with ADP-ribose (S167L mutation) | NSP3 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6WOJ | SARS-CoV-2 | ADP-ribose | 3 | Institut Hospital del Mar d'Investigacions Mèdiques | 33341 | AceMD 3.2.3 | CHARMM36 2019 | |
Open | NSP5 Apo form | NSP5 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 | 6LU7 | SARS-CoV-2 | 2 | Exscalate4CoV - CINECA | 9364 | GROMACS 2020.2 | AMBER 99 | ||
Open | Nucleoprotein | N | Nucleoprotein | NCAP_SARS2 | P0DTC9 | 6VYO | SARS-CoV-2 | 1 | Exscalate4CoV - CINECA | 7782 | GROMACS 2020.2 | AMBER 99 | ||
Open | NSP-13 Helicase | NSP13 | Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 |
Theoretical model (Template: 6JYT) |
SARS-CoV-2 | 1 | Exscalate4CoV - CINECA | 9294 | GROMACS 2020.2 | AMBER 99 | ||
Open | NSP14/NSP10 |
NSP14, NSP10 |
Replicase polyprotein 1ab | R1AB_SARS2 | P0DTD1 |
Theoretical model (Template: 5c8s) |
SARS-CoV-2 | 1 | Exscalate4CoV | 5149 | GROMACS 2020.2 | AMBER 99 | ||
Open | Fully-glycosylated S protein (head) in open-closed-closed state in complex with antibody c002 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 7K8T | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 75321 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-open-closed state in complex with antibody c002 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 7K8U | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 75069 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-closed-closed state in complex with antibody c105 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | - | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 68086 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-open-closed state in complex with antibody c105 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6XCM | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 71414 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-open-open state in complex with antibody c105 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6XCN | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 74742 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in closed-closed-closed state in complex with antibody c119 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | - | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 75306 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-closed-closed state in complex with antibody c119 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 7K8W | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 75306 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-open-closed state in complex with antibody c119 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | - | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 75306 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-closed-closed state in complex with antibody c121 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 7K8X | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 75273 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-open-closed state in complex with antibody c121 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 7K8Y | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 75273 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-open-open state in complex with antibody ey6a | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6ZDH | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 84309 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in closed-closed-closed state in complex with antibody s309 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6WPS | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 74904 | GROMACS 2018.6 | CHARMM36(m) - | ||
Open | Fully-glycosylated S protein (head) in open-closed-closed state in complex with antibody s309 | Spike | Spike glycoprotein | SPIKE_SARS2 | P0DTC2 | 6WPT | SARS-CoV-2 | 1 | Lehigh University, Bethlehem (CHARMM-GUI) | 74769 | GROMACS 2018.6 | CHARMM36(m) - |